Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-24
    E.g., 2018-02-24


19185 items
4:48 PM, Feb 09, 2018  |  BioCentury | Politics, Policy & Law

Money in your pocket

Under intense pressure from President Donald Trump to take steps that visibly lower the cost of drugs, HHS Secretary Alex Azar is reaching for low-hanging fruit. The administration’s proposed budget, which will be released on...
2:36 PM, Feb 09, 2018  |  BioCentury | Finance

Elites always welcome

The fact that 69 biotechs have raised $6.1 billion via IPO financings on NASDAQ since the start of 2016 might suggest the IPO window has remained wide open in the U.S. A closer look at...
1:28 PM, Feb 09, 2018  |  BioCentury | Emerging Company Profile

Fast boat to China

Abbisko Therapeutics aims to be first-to-market for common cancer indications in China with small molecules against clinically validated targets that are more potent than competing agents in development outside the country. Abbisko is focusing first on...
4:00 PM, Feb 06, 2018  |  BioCentury | Regulation

Europe’s common data conundrum

The benefits of deploying a common data model for pharmacovigilance surveillance and postmarket studies are clear, but an EMA workshop held in December to discuss different models highlighted challenges to implementation. Topping the list are sources...
3:05 PM, Feb 06, 2018  |  BioCentury | Finance

Stepping up in Europe

After closing one of Europe’s largest ever life sciences VC funds, Edmond de Rothschild Investment Partners now has the firepower to follow portfolio companies longer and put more capital to work in a wider variety...
6:09 PM, Feb 02, 2018  |  BioCentury | Strategy

Road to acquisition

Sanofi’s proposed acquisition of Ablynx N.V. puts considerable value not only on the Belgian biotech’s lead hematology asset caplacizumab, but also on its Nanobody platform, which fits the pharma’s R&D strategy of prioritizing development of...
5:36 PM, Feb 02, 2018  |  BioCentury | Emerging Company Profile

Going non-viral

Generation Bio Co. aims to take gene therapies into pediatric and other indications where adeno-associated virus vectors have not been able to go. The company is developing preclinical gene therapies that are encoded in eukaryotic closed-ended...
3:09 PM, Feb 02, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 12 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) Nine-month EPS; (C) Fiscal 2Q; (D) During trading hours in Europe; premarket on U.S. exchange;...
2:30 PM, Feb 02, 2018  |  BioCentury | Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
2:27 PM, Feb 02, 2018  |  BioCentury | Finance

Building momentum

Avrobio Inc. parlayed positive clinical data and an aggressive in-licensing strategy into a $60 million series B round that will fund early clinical development of three long-acting lysosomal storage disease candidates. Cormorant Asset Management and Surveyor...